SNY$51.92
$52.15
Chart
Performance
Key Stats
AI SNY Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuySanofi exhibits a stable financial profile and a strong position in the healthcare sector. While recent performance metrics are mixed, its consistent dividend payments and diversified product pipeline offer a degree of resilience. Thematic exposure to healthcare and pharmaceuticals remains a long-term positive, but current technical indicators suggest caution for short-term traders.
Thematic
Sanofi benefits from consistent demand in the healthcare sector, driven by an aging global population and advancements in medical treatments. Its diversified portfolio across various therapeutic areas and vaccines provides a stable growth outlook.
Fundamental
Sanofi demonstrates robust profitability and a healthy balance sheet, with a consistent track record of dividend payments. While revenue growth has been moderate, the company manages its debt effectively and generates substantial free cash flow.
Technical
Sanofi's stock price is currently trading near its 52-week range, with mixed signals from technical indicators. While some moving averages suggest a bullish trend, oscillators like the RSI indicate a neutral to slightly overbought condition, suggesting potential for consolidation or a minor pullback.
| Factor | Score |
|---|---|
| Healthcare Demand | 90 |
| Pharmaceutical Innovation | 80 |
| Vaccine Market | 70 |
| Regulatory Landscape | 60 |
| Geographic Diversification | 85 |
| Factor | Score |
|---|---|
| Valuation | 65 |
| Profitability | 70 |
| Growth | 50 |
| Balance Sheet Health | 80 |
| Cash Flow | 85 |
| Dividend Yield | 70 |
| Factor | Score |
|---|---|
| Trend Analysis | 60 |
| Momentum | 65 |
| Support & Resistance | 70 |
| Volume Confirmation | 70 |
| Short-term Indicators | 55 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Positive Earnings Surprises
Sanofi has demonstrated a pattern of positive earnings surprises, exceeding analyst estimates in several recent quarters (e.g., Q3 2024, Q2 2024). This indicates effective operational management and forecasting.
Strong Cash Position
Sanofi maintains a substantial cash and cash equivalents balance (e.g., $7.441 billion as of Q4 2024), providing significant financial flexibility for operations, investments, and potential acquisitions.
Bearish Points (7)
Inconsistent Quarterly Earnings
There have been significant earnings misses and negative surprises in some quarters (e.g., Q1 2024 EPS estimate vs. reported, Q3 2023 EPS surprise), indicating potential volatility in earnings generation.
High Quarterly P/S Ratio
The Price-to-Sales ratio for Q1 2025 and Q4 2024 (12.2 and 14.7 respectively) appears very high, suggesting that the market is valuing revenue generation at a premium, which might be unsustainable if growth falters.
Calendar
May 2025
9
Ex-Dividend Date
June 2025
12
Next Dividend Date
July 2025
31
Next Earnings Date
H: $1.04
A: $1.00
L: $0.96
H: 10.57B
A: 10.01B
L: 9.64B
Profile
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, yellow fever, and rabies vaccines. In addition, the company has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab, as well as an strategic alliance with the Department of Health Abu Dhabi for the development of global vaccines. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Seasonals
Price Target
62.57 USD
The 39 analysts offering 1 year price forecasts for SNY have a max estimate of 67.80 and a min estimate of 56.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct Competitor: Diversified global healthcare company competing across pharmaceuticals, medical devices, and consumer health, mirroring Sanofi's broad portfolio.
Weight: 90
Direct Competitor: Leading global pharmaceutical company with a broad portfolio including vaccines, oncology, and immunology, often competing directly with Sanofi's core areas.
Weight: 90
Direct Competitor: Major pharmaceutical firm with strong presence in oncology (Keytruda) and vaccines (Gardasil, HPV), areas where Sanofi also has significant interest.
Weight: 88
Direct Competitor: Swiss-based global pharmaceutical company, a peer in various therapeutic areas including immunology, neuroscience, and cardiovascular.